4.7 Article

The HRA2pl fusion peptide exerts in vitro antiviral activity against human respiratory paramyxoviruses and pneumoviruses

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fcimb.2023.1125135

关键词

acute respiratory infections; human respiratory virus; paramyxovirus; pneumovirus; fusion peptide; syncytium size

向作者/读者索取更多资源

Acute respiratory infections, mainly affecting children under the age of 5 and immunocompromised senior adults, are a major cause of morbidity in Mexico. The human respiratory syncytial virus, human metapneumovirus, and human parainfluenza-2 are responsible for many respiratory infections, and current treatment options are limited. In this study, the HRA2pl peptide, targeting the fusion protein of hMPV, showed promising antiviral activity in inhibiting viral entry and reducing viral titer in clinical samples. These findings suggest the potential of HRA2pl as a therapeutic option and warrant further clinical trials.
Acute respiratory infections are a group of diseases caused by viruses, bacteria, and parasites that mainly affect children until the age of 5 and immunocompromised senior adults. In Mexico, these infections are the main cause of morbidity in children, with more than 26 million cases of respiratory infections reported by the Secretariat of Health, in 2019. The human respiratory syncytial virus (hRSV), the human metapneumovirus (hMPV), and the human parainfluenza-2 (hPIV-2) are responsible for many respiratory infections. Currently, palivizumab, a monoclonal antibody against the fusion protein F, is the treatment of choice against hRSV infections. This protein is being studied for the design of antiviral peptides that act by inhibiting the fusion of the virus and the host cell. Therefore, we examined the antiviral activity of the HRA2pl peptide, which competes the heptad repeat A domain of the F protein of hMPV. The recombinant peptide was obtained using a viral transient expression system. The effect of the fusion peptide was evaluated with an in vitro entry assay. Moreover, the effectiveness of HRA2pl was examined in viral isolates from clinical samples obtained from patients with infections caused by hRSV, hMPV, or hPIV-2, by evaluating the viral titer and the syncytium size. The HRA2pl peptide affected the viruses' capacity of entry, resulting in a 4-log decrease in the viral titer compared to the untreated viral strains. Additionally, a 50% reduction in the size of the syncytium was found. These results demonstrate the antiviral potential of HRA2pl in clinical samples, paving the way toward clinical trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据